Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276470 · ClinicalTrials.gov registry record
Environmental Risk Factors for the Anti-synthetase Syndrome
A clinical trial of Dermatomyositis and Polymyositis, sponsored by National Institute of Environmental Health Sciences (NIEHS).
- Recruiting
- Registry status
- 580
- Enrollment target
- 8
- Study locations
NCT01276470: Recruiting study of Dermatomyositis and Polymyositis, sponsored by National Institute of Environmental Health Sciences (NIEHS).
NCT01276470 is a study of Dermatomyositis and Polymyositis that is actively recruiting participants, run by National Institute of Environmental Health Sciences (NIEHS). The registered enrollment target is 580 participants, above the 454-participant average among 19 other Dermatomyositis trials with a reported enrollment target (28% higher). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01276470, a study of Dermatomyositis and Polymyositis, is actively recruiting participants, sponsored by National Institute of Environmental Health Sciences (NIEHS).
- RECRUITING
- Registry status
- 580 participants
- Enrollment target
- 8
- Study locations
Study Summary
Background: * Like other complex diseases, autoimmune diseases are the result of numerous causes, including genetic and environmental factors. Some researchers believe that people who are susceptible to autoimmune disorders develop them when the body reacts to environmental or other factors by creating white blood cells that attack the body s own tissues, which then progresses to autoimmune diseases. These immune-triggered disorders can overlap with one another to some extent, but most autoimmune diseases have certain distinct triggers. * The autoimmune disorder myositis weakens the muscles and may cause other health problems. Environmental exposures associated with myositis include ultraviolet radiation, stressful life events and muscle overexertion, collagen implants, infections such as retroviruses and streptococci bacteria, and certain drugs and chemicals. Some individuals with myositis also produce proteins in the blood called autoantibodies that react with certain parts of the person s own cells, called synthetases, which are involved in making new proteins. A syndrome called the anti-synthetase syndrome, which includes myositis and lung disease, is associated with having the anti-synthetase autoantibodies. Researchers are interested in studying differences in environmental exposures in individuals with myositis. This study is being conducted to determine if persons with the anti-synthetase syndrome have had different environmental exposures before disease onset compared with other patients with myositis who do not have this syndrome and also compared with healthy volunteers. Objectives: \- To determine whether selected infectious and noninfectious environmental exposures are more common in individuals who have myositis with the anti-synthetase syndrome, compared with healthy volunteers. Eligibility: \- Individuals who have been diagnosed with myositis (with or without anti-synthetase autoantibodies), and healthy volunteers without autoimmune disorders.
Primary Outcome
Environmental Questionnaire (EQ) and Child Environmental Questionnaire (CQ)
Conditions Studied
Study Locations (8)
Maryland
- Johns Hopkins University - Baltimore
- National Institutes of Health Clinical Center - Bethesda
- Mid-Atlantic Kaiser Permanente - Rockville
Florida
- University of Miami Hospital - Miami
Massachusetts
- Brigham and Women's Hospital - Boston
Minnesota
- Mayo Clinic, Rochester - Rochester
North Carolina
- NIEHS Clinical Research Unit (CRU) - Research Triangle Park
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 580 participants |
| Start Date | 2011-02-09 |
What NCT01276470 shows while recruiting
NCT01276470 is an observational study that tracks outcomes without assigning an intervention. The registered 580 participants enrollment target is mid-sized for trials with a published cap, above the 454-participant average among 19 other Dermatomyositis trials with a reported enrollment target (28% higher).
The record links to 5 conditions, with Dermatomyositis appearing as the primary indexed condition, and to 0 interventions.
NCT01276470 lists 8 locations in 6 states (Maryland, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT01276470 about?
NCT01276470 is a clinical study titled "Environmental Risk Factors for the Anti-synthetase Syndrome". Background: * Like other complex diseases, autoimmune diseases are the result of numerous causes, including genetic and environmental factors. Some researchers believe that people who are susceptible to autoimmune disorders develop them when the body reacts to environmental or other factors by crea...
What is the current status of trial NCT01276470?
This trial is currently recruiting. The enrollment target is 580 participants. The study started on 2011-02-09.
What conditions does trial NCT01276470 study?
This clinical trial studies the following conditions: Dermatomyositis, Polymyositis, Myositis, Juvenile Dermatomyositis, Juvenile Polymyositis.
Who is sponsoring clinical trial NCT01276470?
This trial is sponsored by National Institute of Environmental Health Sciences (NIEHS), which has 145 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01276470 being conducted?
This trial has 8 study locations across Florida, Maryland, Massachusetts, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatomyositis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01276470's enrollment target sits among peer trials
580 4th of 19 higher than 16 of 19 other Dermatomyositis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatomyositis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
RECRUITING · Phase 3
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
RECRUITING
-
Adult and Juvenile Myositis
RECRUITING
-
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RECRUITING · Phase 2
-
Rheumatology Patient Registry and Biorepository
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04575935 · 580 participants · Phase 3
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- NCT05143177 · 580 participants · Phase 2
A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
- NCT05696353 · 580 participants · Phase 3
Teen Driving Translation Study (NIH)
- NCT06578104 · 580 participants
PULSED AF Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI